The purpose of this study was to determine if the penetration enhancer SEPATM (2-n-nonyl-1,3-dioxolane) would augment the scalp hair growth effects of topical minoxidil in the balding stumptail macaque. A 1-in2 area on the balding scalp of 40 adult female monkeys (four drug-treated and four vehicle-treated groups of 5 monkeys each) was topically treated 5 days/week, q.d. or b.i.d., with approximately 250 µl of minoxidil-SEPATM (2.5% minoxidil, weight/volume in 10% SEPATM, 25% propylene glycol and 65% isopropyl alcohol), Rogaine® topical solution (TS, 2% minoxidil, weight/volume in 20% propylene glycol, 60% ethanol and 20% water) or respective vehicles (without drug) for 16 weeks via paintbrush application. Scalp hair was collected by shaving and vacuuming the dosed area at baseline and at 4-week intervals. The shaved hair was filtered, weighed and recorded as the change from baseline. The q.d. and b.i.d. minoxidil-SEPATM groups displayed a significant increase in hair weight compared to their respective vehicles at week 4 whereas q.d. and b.i.d. Rogaine® TS groups were not active until week 8 and 12, respectively. Both minoxidil-SEPATM treatments produced significantly greater cumulative hair weight over the entire 16-week study compared to either of the Rogaine® TS treatments. Comparable increases in cumulative hair weight were evident between q.d. and b.i.d. minoxidil-SEPATM groups and between q.d. and b.i.d. Rogaine® TS groups. Twenty-four-hour urine samples were collected at steady state to assess urinary excretion of total minoxidil via high performance liquid chromatography analysis in each of the four drug-treated groups. Urinary levels of total minoxidil tended to be greater in minoxidil-SEPATM groups. However, due to high intragroup variation, only the b.i.d. minoxidil-SEPATM group showed a significant 2.8-fold elevation compared to the b.i.d. Rogaine® TS group. These data suggest that the penetration enhancer SEPATM influences the topical delivery of minoxidil resulting in earlier and greater stimulation of scalp hair growth in the balding stumptail macaque.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.